Org41841
Based on 1 Customer Validation
Org41841 is a partial agonist of both luteinizing hormone/chorionic gonadotropin receptor (LHCGR) and thyroid-stimulating hormone receptor (TSHR) with EC50s of 0.2 and 7.7 μM, respectively.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度 : 99.77%
- CAS 番号: 301847-37-0
- 分子式: C19H22N4O2S2
- 分子量:402.53
-
保管条件:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- プロトコル
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
-
HY-12381
ML224TSHR Antagonist -
HY-114116
ML-109TSHR Agonist -
HY-129995A
TSHR antagonist S37aTSHR Antagonist -
HY-100271R
Org41841 (Standard)LHCGR/TSHR Partial Agonist -
HY-124867
D3-βArrTSH Receptor Modulator -
HY-122974
VA-K-14 hydrochlorideTSHR Antagonist -
HY-153213
Org 274179-0TSH Receptor Antagonist -
HY-18286
NCGC00229600TSHR Inverse Agonist -
HY-129995
TSHR antagonist S37bTSHR Inhibitor
生物活性
製品説明
IC50 & Target
EC50: 0.2 μM (LHCGR), 7.7 μM (TSHR)[1]
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HEK293 | EC50 |
0.3 μM
Compound: 3,Org 41841
|
Agonist activity at LHCGR expressed in HEK293 EM cells measured by intracellular cAMP accumulation
Agonist activity at LHCGR expressed in HEK293 EM cells measured by intracellular cAMP accumulation
|
[PMID: 16789744] |
| HEK293 | EC50 |
6.5 μM
Compound: 3,Org 41841
|
Agonist activity at TSHR expressed in HEK293 EM cells measured by intracellular cAMP accumulation
Agonist activity at TSHR expressed in HEK293 EM cells measured by intracellular cAMP accumulation
|
[PMID: 16789744] |
体外実験
Functional assays demonstrate that Org41841 is a partial agonist of both luteinizing hormone/chorionic gonadotropin receptor (LHCGR) and thyroid-stimulating hormone receptor (TSHR) with EC50s of 0.2 and 7.7 μM, respectively. Treatment of L570F with Org41841 reveals an improved EC50 of 800 nM. M9 responds to Org41841 with an improved EC50 of 2700 nM and a greatly improved efficacy for signaling to 99% of the maximal value observed for thyroid-stimulating hormone (TSH) stimulation of thyroid-stimulating hormone receptor (TSHR)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
化学情報
-
CAS 番号 301847-37-0
-
性状 Solid
-
分子量 402.53
-
分子式 C19H22N4O2S2
-
Color White to yellow
-
SMILES
O=C(C1=C(N)C2=C(C3=CC=CC(OC)=C3)N=C(SC)N=C2S1)NC(C)(C)C
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
溶剤 & 溶解度
体外:
DMSO : 100 mg/mL (248.43 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
プロトコル
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
純度とドキュメンテーション
-
データシート (277 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
取扱説明書 (2659 KB)
参考文献
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.4843 mL | 12.4214 mL | 24.8429 mL | 62.1072 mL |
| 5 mM | 0.4969 mL | 2.4843 mL | 4.9686 mL | 12.4214 mL | |
| 10 mM | 0.2484 mL | 1.2421 mL | 2.4843 mL | 6.2107 mL | |
| 15 mM | 0.1656 mL | 0.8281 mL | 1.6562 mL | 4.1405 mL | |
| 20 mM | 0.1242 mL | 0.6211 mL | 1.2421 mL | 3.1054 mL | |
| 25 mM | 0.0994 mL | 0.4969 mL | 0.9937 mL | 2.4843 mL | |
| 30 mM | 0.0828 mL | 0.4140 mL | 0.8281 mL | 2.0702 mL | |
| 40 mM | 0.0621 mL | 0.3105 mL | 0.6211 mL | 1.5527 mL | |
| 50 mM | 0.0497 mL | 0.2484 mL | 0.4969 mL | 1.2421 mL | |
| 60 mM | 0.0414 mL | 0.2070 mL | 0.4140 mL | 1.0351 mL | |
| 80 mM | 0.0311 mL | 0.1553 mL | 0.3105 mL | 0.7763 mL | |
| 100 mM | 0.0248 mL | 0.1242 mL | 0.2484 mL | 0.6211 mL |
Org41841 関連分類
HY-100271 関連分類
Powered by Bioz